XML 75 R65.htm IDEA: XBRL DOCUMENT
v3.20.2

INVESTMENTS - RELATED PARTIES (Details 1) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019
Fair value of derivative instruments issued by AVLP | $ 10,184 | $ (946,825) | $ 5,773 | $ (946,825) |
Avalanche International Corp. ("AVLP") and Alzamend Neuro, Inc. ("Alzamend") [Member] |  |  |  |  |
Investment in common stock of AVLP and Alzamend |  |  | 575,925 |  | $ 558,938
Avalanche International Corp. ("AVLP") and Alzamend Neuro, Inc. ("Alzamend") [Member] | Warrants and Common Stock [Member] |  |  |  |  |
Balance at beginning |  |  | 2,128,224 |  |
Investment in convertible promissory notes of AVLP |  |  |  |  |
Investment in common stock of AVLP and Alzamend |  |  | 12,884 |  |
Fair value of derivative instruments issued by AVLP |  |  | 9,093 |  |
Unrealized loss in derivative instruments of AVLP |  |  | (481,213) |  |
Unrealized loss in common stock of AVLP and Alzamend |  |  | (64,639) |  |
Balance at end | 1,604,349 |  | 1,604,349 |  | 2,128,224
Avalanche International Corp. [Member] | 8% Convertible Promissory Note [Member] |  |  |  |  |
Balance at beginning |  |  | 6,540,720 |  |
Investment in convertible promissory notes of AVLP |  |  | 198,514 |  |
Investment in common stock of AVLP and Alzamend |  |  |  |  |
Fair value of derivative instruments issued by AVLP |  |  |  |  |
Unrealized loss in derivative instruments of AVLP |  |  |  |  |
Unrealized loss in common stock of AVLP and Alzamend |  |  |  |  |
Balance at end | 6,739,234 |  | 6,739,234 |  | 6,540,720
Avalanche International Corp. ("AVLP") and Alzamend Neuro, Inc. ("Alzamend") [Member] |  |  |  |  |
Balance at beginning |  |  | 8,668,944 |  |
Investment in convertible promissory notes of AVLP |  |  | 198,514 |  |
Investment in common stock of AVLP and Alzamend |  |  | 12,884 |  |
Fair value of derivative instruments issued by AVLP |  |  | 9,093 |  |
Unrealized loss in derivative instruments of AVLP |  |  | (481,213) |  |
Unrealized loss in common stock of AVLP and Alzamend |  |  | (64,639) |  |
Balance at end | $ 8,343,583 |  | $ 8,343,583 |  | $ 8,668,944

X
- Definition The amount of common stock acquired during the period. + References No definition available. + Details
Name: | dpw_InvestmentInCommonStock1
Namespace Prefix: | dpw_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Investment in convertible promissory notes. + References No definition available. + Details
Name: | dpw_InvestmentInConvertiblePromissoryNotes
Namespace Prefix: | dpw_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of total investment in net. + References No definition available. + Details
Name: | dpw_TotalInvestmentInNet1
Namespace Prefix: | dpw_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of warrant. + References No definition available. + Details
Name: | dpw_UnrealizedGainOnWarrant
Namespace Prefix: | dpw_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section 25 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875 + Details
Name: | us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period. + References No definition available. + Details
Name: | us-gaap_UnrealizedGainOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dpw_AvalancheInternationalCorpAndAlzamendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=dpw_WarrantsAndCommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dpw_AvalancheInternationalCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=dpw_ConvertiblePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dpw_AvalancheInternationalCorpAndAlzamendNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |